LYEL
Ticker
Lyell Immunopharma, Inc.
LYEL · Healthcare · Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for pat…Lyell Immunopharma, Inc. (LYEL), in the Healthcare sector, has 4 disclosed filings on Paydirt over the trailing twelve months from 3 corporate insiders: 2 purchases and 2 sales. Filers took a median of 3 days from execution to disclosure, and the most recent trade was executed Aug 21 and filed Aug 25. The most active filer was Lynn Seely with 3 filings.
Add to watchlistFilings, ttm
4
2 buys · 2 sells
Traders, ttm
3
3 insiders
Volume, ttmiDollar value disclosed in the window
$25.3M
estimated for Congress, as filed for insiders
Median delay
3d
execution to disclosure
Last traded
Aug 21
Filed Aug 25
ADViAverage daily dollar volume
$2.9M
market data
Share price · 12M
$14.53 (+10.3%)
Adjusted for splits and dividends.
Volume by month
Buys $25.0M
Sells $323K
Estimated for Congress, as filed for insiders · by filing month · past 24 months
Who filed
LSRecent filings
Lynn SeelySALE
President and CEO
$149K9,589 sh × $15.54
Exec Aug 21
Filed Aug 25 · 4:06 PM ET ARCH Venture Partners IX, LLCPURCHASE 10% owner $12.5M
488,090 sh × $25.61
Exec Mar 6
Filed Mar 9 · 4:36 PM ET ARCH Venture Fund XIII, L.P.PURCHASE 10% owner $12.5M
488,090 sh × $25.61
Exec Mar 6
Filed Mar 9 · 4:34 PM ET Lynn SeelySALE President and CEO $174K
7,455 sh × $23.39
Exec Feb 11
Filed Feb 12 · 5:30 PM ET Sumant RamachandraPURCHASE Director –
200,000 sh · price not plausible
Exec Mar 21 2025
Filed Mar 25 2025 · 5:30 PM ET Lynn SeelyPURCHASE President and CEO –
175,000 sh · price not plausible
Exec Mar 14 2025
Filed Mar 18 2025 · 5:30 PM ET Charles W. NewtonPURCHASE Chief Financial Officer –
200,000 sh · price not plausible
Exec Mar 17 2025
Filed Mar 18 2025 · 5:30 PM ET